Guru Fundamental Report for JNJ

Johnson & Johnson (JNJ) received a 77% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy for identifying low book-to-market stocks with sustained future growth. The large-cap biotechnology and drugs stock, while passing most growth criteria including return on assets and cash flow, notably failed tests for advertising and R&D to assets, positioning it just below the 80% threshold for strategic 'interest' according to this specific academic-derived model.

Analysis

Johnson & Johnson (JNJ) scores a 77% rating according to Validea's P/B Growth Investor model, a framework derived from Partha Mohanram's academic research designed to identify low book-to-market stocks with potential for sustained growth. This score places JNJ just below the 80% threshold that indicates strategic interest from the model. The analysis reveals a mixed profile: JNJ demonstrates strong underlying fundamentals, passing crucial tests for Return on Assets, Cash Flow From Operations to Assets, and stability in both ROA and sales variance. These metrics suggest high operational efficiency and quality of earnings. However, the model highlights significant weaknesses by failing JNJ on two forward-looking growth indicators: Advertising to Assets and Research and Development to Assets. For a large-cap firm in the Biotechnology & Drugs industry, an apparent underinvestment in R&D is a particularly notable flag, suggesting that while the company is currently stable and profitable, its commitment to future growth drivers may be insufficient to meet this specific model's criteria for outperformance.

Key Decisions for Investors

• Investors should recognize that while JNJ displays strong fundamentals in profitability and cash flow, its rating is constrained by perceived underinvestment in R&D and advertising, making it a potentially more suitable holding for quality-focused rather than aggressive growth portfolios.
• A key area for due diligence is JNJ's R&D spending and pipeline, as the model's failure on this criterion is a significant flag for a company in the Biotechnology & Drugs industry and could impact long-term growth prospects.
• Consider monitoring future quarterly reports for changes in advertising and R&D expenditure relative to assets, as an increase could signal a strategic shift towards growth that might trigger a higher rating from this specific model.